Pınar Öztürk, MD is a neurologist at the Department of Neurology, Ankara Yıldırım Beyazıt University Yenimahalle Training and Research Hospital in Ankara, Türkiye. She graduated from Ankara University Faculty of Medicine in 2011 and completed her neurology residency at Ankara Atatürk Training and Research Hospital in 2017. She has been working as a neurology specialist at Yenimahalle Training and Research Hospital since 2019.
Her research interests include demyelinating diseases, migraine, systemic inflammatory and hematological biomarkers, treatment outcomes, and patient-centered clinical variables. Her academic work has addressed migraine-related biomarkers and suicidal ideation, antiepileptic drug use during pregnancy, hearing loss as a potentially modifiable risk factor for dementia, and pain-related issues in neurological practice. She has contributed to national and international publications, congress presentations, and academic book chapters, including work on myelin oligodendrocyte glycoprotein (MOG)-associated disease.
Pınar Öztürk, MD is a neurologist at the Department of Neurology, Ankara Yıldırım Beyazıt University Yenimahalle Training and Research Hospital in Ankara, Türkiye. She graduated from Ankara University Faculty of Medicine in 2011 and completed her neurology residency at Ankara Atatürk Training and Research Hospital in 2017. She has been working as a neurology specialist at Yenimahalle Training and Research Hospital since 2019.
Her research interests include demyelinating diseases, migraine, systemic inflammatory and hematological biomarkers, treatment outcomes, and patient-centered clinical variables. Her academic work has addressed migraine-related biomarkers and suicidal ideation, antiepileptic drug use during pregnancy, hearing loss as a potentially modifiable risk factor for dementia, and pain-related issues in neurological practice. She has contributed to national and international publications, congress presentations, and academic book chapters, including work on myelin oligodendrocyte glycoprotein (MOG)-associated disease.